search
Fierce Pharma
Trends
- 1Novo Nordisk and Hengrui strike $2.6bn obesity drug deal▼Novo and Hengrui strike $2.6bn obesity drug deal
Danish drugmaker Novo Nordisk has agreed a deal worth $2.6 billion with China's Hengrui Pharmaceuticals, giving Novo rights to an obesity drug candidate. The agreement underscores fierce competition in the fast-growing weight-loss drug market, where Novo's Wegovy faces mounting rivalry from Eli Lilly and emerging Chinese developers.